[Sisomicine in the lumbar and ventricular cerebrospinal fluid. Concentration after intramuscular or intrathecal injection. Study in 14 subjects-therapeutic implications (author's transl)].
Following intramuscular injection sisomicine, in common with other aminosides, shows poor intrathecal diffusion (less than 10% of serum levels) even during the initial phase of purulent meningitis. Following the intraspinal or intraventricular injection of 0.5 mg/kg, high levels are obtained which persist up to 48th hour. This dose is very well tolerated and no accumulation phenomena were demonstrated after repeated injections. In cases of meningitis due to organisms resistant to diffusible antibiotics, sisomicine sulphate may be used by lumbar intraspinal or sometimes intraventricular injection in severe forms, in a dose of 0.5 mg/kg every 48 hours (or even 24 hours). In combination with systemic treatment. The duration of treatment cannot be precisely defined.
D000293:Adolescent; D000328:Adult; D000368:Aged; D005839:Gentamicins / Q000008:administration & dosage*; D006801:Humans; D007273:Injections, Intramuscular; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008590:Meningoencephalitis / Q000134:cerebrospinal fluid / Q000188:drug therapy; D008875:Middle Aged; D012853:Sisomicin / Q000008:administration & dosage* / Q000134:cerebrospinal fluid / Q000627:therapeutic use
D005839:Gentamicins; D012853:Sisomicin
Sisomicine dans le liquide céphalo-rachidien lombaire et ventriculaire: concentrations après injection intra-musculaire ou intra-thécale. Etude chez 14 sujets--implications thérapeutiques.